These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 2449057)
21. [Alfuzosin in benign prostatic hyperplasia. A new principle is evaluated. Report of a study]. Fortschr Med Suppl; 1995; 166():1-12. PubMed ID: 7537599 [No Abstract] [Full Text] [Related]
22. [The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin]. Mazo EB; Matushevskiĭ IA; Nikitin IuIu Ter Arkh; 1997; 69(10):79-82. PubMed ID: 9471799 [TBL] [Abstract][Full Text] [Related]
24. [Generally effective for unstable bladder? Tamsulosin: application not limited to benign prostatic hyperplasia]. Urologe A; 2003 Feb; 42(2):301-2. PubMed ID: 12739514 [No Abstract] [Full Text] [Related]
25. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms. Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690 [TBL] [Abstract][Full Text] [Related]
26. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766 [TBL] [Abstract][Full Text] [Related]
27. [Long-term therapy with Robaveron tablet (KN-7) for urinary disturbance]. Tei K; Doi T; Sakai S; Fujimoto Y; Ban Y Hinyokika Kiyo; 1985 Apr; 31(4):731-8. PubMed ID: 2412422 [TBL] [Abstract][Full Text] [Related]
28. Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin Belgian Group. Schulman CC; De Sy W; Vandendris M; Tomas M; Santoni JP Acta Urol Belg; 1994 Dec; 62(4):15-21. PubMed ID: 7540794 [TBL] [Abstract][Full Text] [Related]
29. [Clinical effects of distigmine bromide (Ubretid), a cholinesterase inhibitor, on micturition disturbance by benign prostatic hypertrophy--comparative study of distigmine bromide and the combination of distigmine bromide and adrenergic blocker]. Katsumi T; Murayama K Hinyokika Kiyo; 1992 Sep; 38(9):1089-92. PubMed ID: 1384297 [TBL] [Abstract][Full Text] [Related]
30. [A double blind clinical trial of the alpha-adrenergic blocker, Ea-0643 tablet, in the treatment of neurogenic bladder]. Murayama K; Katsumi T; Nakamura T; Tazika E; Sakai A; Haginaka T Hinyokika Kiyo; 1985 Oct; 31(10):1845-53. PubMed ID: 2868640 [TBL] [Abstract][Full Text] [Related]
31. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes. Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250 [TBL] [Abstract][Full Text] [Related]
32. [Surgery (TUR-P) as a recommended initial treatment modality for the presented case]. Gotoh M Hinyokika Kiyo; 2005 Sep; 51(9):603-8. PubMed ID: 16229373 [TBL] [Abstract][Full Text] [Related]
33. Prostatic and extraprostatic alpha-adrenoceptors--contributions to the lower urinary tract symptoms in benign prostatic hyperplasia. Andersson KE Scand J Urol Nephrol Suppl; 1996; 179():105-11. PubMed ID: 8908675 [TBL] [Abstract][Full Text] [Related]
34. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Gallegos PJ; Frazee LA Pharmacotherapy; 2008 Mar; 28(3):356-65. PubMed ID: 18294115 [TBL] [Abstract][Full Text] [Related]
35. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial. Resnick MI; Roehrborn CG Prostate Cancer Prostatic Dis; 2007; 10(2):155-9. PubMed ID: 17211442 [TBL] [Abstract][Full Text] [Related]
36. [Effects of long-term administration of oxybutynin hydrochloride (KL007) for the treatment of neurogenic bladder and unstable bladder]. Sonoda T; Sakurai T; Yamada K; Mizutani S; Tsujimoto Y; Ogawa T Hinyokika Kiyo; 1989 Jan; 35(1):167-78. PubMed ID: 2658513 [TBL] [Abstract][Full Text] [Related]
37. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. Seftel A J Urol; 2005 Nov; 174(5):1940-1. PubMed ID: 16217354 [No Abstract] [Full Text] [Related]
38. [A clinical trial of the treatment of patients with benign prostatic hyperplasia using the alpha 1-adrenoblocker alfuzosin]. Lopatkin NA; Perepanova TS Urol Nefrol (Mosk); 1997; (5):14-6. PubMed ID: 9412005 [TBL] [Abstract][Full Text] [Related]
39. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Lowe FC Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685 [TBL] [Abstract][Full Text] [Related]
40. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Yokoyama T; Uematsu K; Watanabe T; Sasaki K; Kumon H; Nagai A; Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]